UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 76

Sortiert nach

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Annals of oncology, 2014-03, Vol.25 (3), p.682-688

2014

Volltextzugriff (PDF)

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial

Annals of oncology, 2017-09, Vol.28 (9), p.2219-2224

2017

Volltextzugriff (PDF)

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study

Annals of oncology, 2017-09, Vol.28 (9), p.2213-2218

2017

Volltextzugriff (PDF)

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971 TAX 323)

British journal of cancer, 2010-10, Vol.103 (8), p.1173-1181

2010

Volltextzugriff (PDF)

8533 POSTER First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab+Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck

European journal of cancer (1990), 2011, Vol.47, p.S553-S553

2011

Volltextzugriff (PDF)

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Annals of oncology, 2011-05, Vol.22 (5), p.1078-1087

2011

Volltextzugriff (PDF)

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

European journal of cancer (1990), 2013-05, Vol.49 (7), p.1609-1618

2013

Volltextzugriff (PDF)

Cetuximab and platinum-based chemoradio-or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

British journal of cancer, 2013-09, Vol.109 (5), p.1117-1122

2013

Volltextzugriff (PDF)

The Effect of Leukocyte Interleukin Injection (Multikine®) Treatment on the Peritumoral and Intratumoral Subpopulation of Mononuclear Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity to Radiation Therapy and Chemotherapy in Oral Cancer-A Multicenter Phase I/II Clinical Trial

The Laryngoscope, 2003-12, Vol.113 (12), p.2206-2217

2003

Volltextzugriff (PDF)

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.5508-5508

2004

Volltextzugriff (PDF)

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.5508-5508

2004

Volltextzugriff (PDF)

OC-021: Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN

Radiotherapy and oncology, 2017-03, Vol.122, p.14-14

2017

Volltextzugriff (PDF)

5548 POSTER Circulating hormone levels and prognosis in head and neck cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.338-338

2007

Volltextzugriff (PDF)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase 1/11 ADVANTAGE trial (phase II part)

Annals of oncology, 2014, Vol.25 (3), p.682-688

2014

Volltextzugriff (PDF)

Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5530-5530

2011

Volltextzugriff (PDF)

Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer

International journal of oncology, 2007-01, Vol.30 (1), p.155-160

2007

Volltextzugriff (PDF)

Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5505-5505

2010

Volltextzugriff (PDF)

Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.6005-6005

2009

Volltextzugriff (PDF)

Mutagen sensitivity of patients with cancer at different sites of the head and neck

Mutagenesis, 2005-09, Vol.20 (5), p.381-385

2005

Volltextzugriff (PDF)

Malignant mucosal melanoma of the head and neck

Pathology oncology research, 2003, Vol.9 (1), p.7-12

2003

Volltextzugriff (PDF)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Annals of oncology, 2014-03, Vol.25 (3), p.682

2014

Volltextzugriff (PDF)

Molecular identification, expression and prognostic role of estrogen-and progesterone receptors in head and neck cancer

International journal of oncology, 2006, Vol.30 (1), p.155-160

2006

Volltextzugriff (PDF)

Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.5537-5537

2006

Volltextzugriff (PDF)

Does the bleomycin sensitivity assay express cancer phenotype?

Mutagenesis, 2003-01, Vol.18 (1), p.59-63

2003

Volltextzugriff (PDF)

Leukocyte interleukin, injection (LI) treatment in advanced primary squamous cell carcinoma of the head & neck a phase II multi-center trial and pathology study

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2605-2605

2004

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(74)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(37)
Science & Technology
(31)
Male
(27)
Life Sciences & Biomedicine
(26)
Female
(24)
Adult
(22)
Middle Aged
(21)
Aged
(19)
Oncology
(18)
Biological And Medical Sciences
(12)
Medical Sciences
(10)
Treatment Outcome
(9)
Tumors
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Head And Neck Neoplasms - Drug Therapy
(8)
Head And Neck Neoplasms - Pathology
(8)
Otorhinolaryngology. Stomatology
(8)
Carcinoma, Squamous Cell - Drug Therapy
(7)
Carcinoma, Squamous Cell - Pathology
(7)
Head And Neck Cancer
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971 TAX 323)

8533 POSTER First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab+Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease

Cetuximab and platinum-based chemoradio-or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)

OC-021: Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN

5548 POSTER Circulating hormone levels and prognosis in head and neck cancer

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase 1/11 ADVANTAGE trial (phase II part)

Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN)

Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer

Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN)

Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN

Mutagen sensitivity of patients with cancer at different sites of the head and neck

Malignant mucosal melanoma of the head and neck

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Molecular identification, expression and prognostic role of estrogen-and progesterone receptors in head and neck cancer

Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME)

Does the bleomycin sensitivity assay express cancer phenotype?

Leukocyte interleukin, injection (LI) treatment in advanced primary squamous cell carcinoma of the head & neck a phase II multi-center trial and pathology study

Suchergebnisse filtern